Hepatitis B virus resistance to antivirals: clinical implications and management.
Zoulim
Fabien
F
INSERM U 271 and Liver Department, Institut Universitaire de France, 151 Cours Albert Thomas, F-69003 Lyon, France. zoulim@lyon.inserm.fr
D000998:Antiviral Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D006509:Hepatitis B / Q000188:drug therapy* / Q000821:virology*; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D011379:Prognosis; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine